Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -310.33% is 91% below its 3-year average of -162.24%, near the low end of its 3-year range (-321.99%–-9.46%).
As of the fiscal period ended Tuesday, June 30, 2026. 31.26% below its 12-month average of -236.43%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -310.33%.
RETURN ON EQUITY (ROE)
-310.33%
RETURN ON EQUITY (ROE) AVG TTM
-236.43%
RETURN ON EQUITY (ROE) AVG 3Y
-162.24%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-31.26%
CURRENT VS 3Y AVG
-91.29%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-638.72%
vs the sector median at left
60 Degrees Pharmaceuticals, Inc.
Market Cap
$3.90M
Return on Equity (ROE)
-310.33%
TTM Avg
-236.43%
3Y Avg
-162.24%
5Y Avg
N/A
Market Cap
$3.93M
Return on Equity (ROE)
-437.15%
TTM Avg
-328.44%
3Y Avg
-188.67%
5Y Avg
-533.64%
Market Cap
$4.21M
Return on Equity (ROE)
N/A
TTM Avg
-470.92%
3Y Avg
-382.96%
5Y Avg
-276.61%
Market Cap
$3.53M
Return on Equity (ROE)
-282.13%
TTM Avg
-313.25%
3Y Avg
-153.55%
5Y Avg
-153.55%
Market Cap
$3.67M
Return on Equity (ROE)
-383.03%
TTM Avg
-1602.50%
3Y Avg
-1094.59%
5Y Avg
-783.90%
Market Cap
$4.24M
Return on Equity (ROE)
N/A
TTM Avg
-201.28%
3Y Avg
-1309.54%
5Y Avg
-838.52%
Market Cap
$3.63M
Return on Equity (ROE)
-5.85%
TTM Avg
-5.85%
3Y Avg
-10.40%
5Y Avg
7.36%
Market Cap
$3.65M
Return on Equity (ROE)
N/A
TTM Avg
5741.84%
3Y Avg
2797.55%
5Y Avg
1847.94%
Market Cap
$4.21M
Return on Equity (ROE)
-424.89%
TTM Avg
-156.14%
3Y Avg
-97.37%
5Y Avg
-86.32%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 60 Degrees Pharmaceuticals, Inc. (SXTP) | $3.90M | -310.33% | -236.43% | -162.24% | N/A |
| Aptevo Therapeutics Inc. (APVO)vs › | $3.93M | -437.15% | -328.44% | -188.67% | -533.64% |
| Processa Pharmaceuticals, Inc. (PCSA)vs › | $4.21M | N/A | -470.92% | -382.96% | -276.61% |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.53M | -282.13% | -313.25% | -153.55% | -153.55% |
| Ernexa Therapeutics Inc. (ERNA)vs › | $3.67M | -383.03% | -1602.50% | -1094.59% | -783.90% |
| GRI Bio, Inc. (GRI)vs › | $4.24M | N/A | -201.28% | -1309.54% | -838.52% |
| WORK Medical Technology Group Ltd. Class A (WOK)vs › | $3.63M | -5.85% | -5.85% | -10.40% | 7.36% |
| Evogene Ltd. (EVGN)vs › | $3.65M | N/A | 5741.84% | 2797.55% | 1847.94% |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.21M | -424.89% | -156.14% | -97.37% | -86.32% |
| Eocene Ltd. (EOCN)vs › | $3.50M | N/A | N/A | N/A | N/A |
ROE
-310.3%
ROA
-189.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -310.33% |
| 2026-03-31 | -157.00% |
| 2025-12-31 | -212.76% |
| 2025-09-30 | -180.04% |
| 2025-06-30 | -321.99% |
| 2025-03-31 | -249.57% |
| 2024-12-31 | -197.02% |
| 2024-09-30 | -130.15% |
| 2024-06-30 | -49.98% |
| 2024-03-31 | -9.46% |
| 2023-12-31 | -76.21% |
| 2023-09-30 | -52.31% |
